|
|
Abstract
Study of electrocardiographic abnormalities in different evolutive phases of HIV/AIDS
Morozov A.1, Feldman M.2, Antonova V.2
Introduction: the cardiac involvement in AIDS has been referred in the medical literature mainly by the presence of the pathologic changes in autopsy. This study objective was to verify electrocardiographical(ECG)abnormalities in different evolutive periods of HIV infection in relation with CD4 count.
Methods: 54 HIV+ male and female patients over 15 years old were examined and submitted to follow up visits in the period of July 2003 and November 2004. At every occasion of ECG recording the following tests were also performed: CD4 and CD8 count by flow cytometry, X-ray of heart area, Hb level and serum levels of LDH. ALl patients had the weight and the clinical evolution determined during the observation period. According to CD4 count they were classified in 3 groups: G1(n=15); CD4 > 400; G2 (n=10): 200 < CD4 < 400; G3 (n=29): CD4 < 200.
Results: ECG recording with abnormalities of any parameter considered (p > 0.25) or even low QRS complexes alone (p > 0.50) were early and frequent findings in the groups (G1=G2=G3). There was significant difference between the following parameters of the groups: CD8 count, weight variation, and number of survivors: (G1=G2) > G3, p < 0.001; Hb: (G1=G2) > G3, p < 0.05; corrected QT interval (QTc): (G1=G2) < G3, p < 0.001.There was a negative correlation between QTc and all the other parameters studied, including CD4 count.
Conclusions: changes in ECG recording can be seen in patients since the clinical latency phase.The QTc is increased during the progressive phase of the disease; generalized low voltage and increased QTc in the ECG recording maybe suggestive of myocardiopathy.
The 3rd IAS Conference on HIV Pathogenesis and Treatment
Abstract no.
TuPe2.3C03
Suggested Citation
"MorozovA., et al.
Study of electrocardiographic abnormalities in different evolutive phases of HIV/AIDS.
Poster Exhibition:
The 3rd IAS Conference on HIV Pathogenesis and Treatment:
Abstract no.
TuPe2.3C03"
|
|
|